Shots:
- Fapon Biopharma has enrolled the first patient in China for its P-I trial of FP008 for advanced solid tumors, conducted at Zhejiang Cancer Hospital. The patient completed the DLT observation with a favorable safety profile. The trial focuses on evaluating FP008’s safety and tolerability
- FP008 demonstrated favorable safety and PK in monkey studies and has received IND approval from both the US FDA and China’s NMPA, supporting its clinical potential
- FP008 is a novel anti-PD-1×IL-10M fusion protein designed for PD-1–naïve or resistant patients. It’s engineered IL-10M reduces hematologic toxicity, while the anti-PD-1 antibody boosts IL-10M activity through PD-1 targeting and cis-activation
Ref: Fapon | Image: Fapon | Press Release
Related News:- Fapon Biopharma Reports the US FDA Approval of IND Application for FP008 to Treat Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
